BTIG Maintains Buy on Castle Biosciences, Lowers Price Target to $40

Castle Biosciences

Castle Biosciences

CSTL

0.00

BTIG analyst Mark Massaro maintains Castle Biosciences (NASDAQ: CSTL) with a Buy and lowers the price target from $50 to $40.